Whitehawk Therapeutics Income Statement Analysis

Revenue, earnings, and profit margins in millions USD

Scroll to see more
Whitehawk Therapeutics, Inc. income statement - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Revenue & Gross Profit
Revenue25.9824.3515.221.1214.58
Cost of Revenue54.0551.741.3419.6715.01
Gross Profit-28.07-27.3813.88-18.55-0.43
Operating Expenses
Research & Development51.0348.9332.6619.670.00
Selling, General & Administrative36.7544.5540.1818.512.12
Operating Expenses39.3944.5572.8418.512.12
Operating Income-67.46-71.93-58.96-37.06-2.55
Other Income/Expense
Interest Income3.936.402.400.010.04
Interest Expense0.15-0.230.23-0.67-0.82
Other Income/Expense3.770.00-3.72-72.380.00
Income
Income Before Tax-63.69-65.77-60.51-110.09-3.48
Income Tax Expense0.000.000.000.000.00
Net Income-63.69-65.77-60.51-110.09-3.48
Net Income - Continuous Operations-63.69-65.77-60.51-110.090.00
Net Income - Discontinued Operations0.000.000.000.000.00
EBITDA-64.63-71.76-60.12-36.96-2.54
EBIT-63.69-71.93-60.28-37.06-2.55
Depreciation & Amortization0.190.170.160.110.01
Earnings Per Share
Basic EPS-2.00-2.00-3.00-12.00-2.00
Diluted EPS-2.00-2.00-3.00-12.00-2.00
Basic Shares Outstanding27.0326.9222.518.922.54
Diluted Shares Outstanding27.0326.9222.518.922.54